JP2002514928A - 脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用 - Google Patents
脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用Info
- Publication number
- JP2002514928A JP2002514928A JP50877199A JP50877199A JP2002514928A JP 2002514928 A JP2002514928 A JP 2002514928A JP 50877199 A JP50877199 A JP 50877199A JP 50877199 A JP50877199 A JP 50877199A JP 2002514928 A JP2002514928 A JP 2002514928A
- Authority
- JP
- Japan
- Prior art keywords
- telomerase
- region
- nucleic acid
- sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010017842 Telomerase Proteins 0.000 title claims abstract description 335
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 163
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 112
- 241000251539 Vertebrata <Metazoa> Species 0.000 title claims abstract description 49
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 137
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 115
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 115
- 238000000034 method Methods 0.000 claims abstract description 102
- 230000000694 effects Effects 0.000 claims abstract description 80
- 239000003112 inhibitor Substances 0.000 claims abstract description 51
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 239000013604 expression vector Substances 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 165
- 239000013615 primer Substances 0.000 claims description 124
- 230000003321 amplification Effects 0.000 claims description 93
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 93
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 68
- 239000013598 vector Substances 0.000 claims description 66
- 239000002299 complementary DNA Substances 0.000 claims description 61
- 230000014509 gene expression Effects 0.000 claims description 59
- 239000000523 sample Substances 0.000 claims description 57
- 125000003729 nucleotide group Chemical group 0.000 claims description 56
- 239000002773 nucleotide Substances 0.000 claims description 53
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 43
- 108091034117 Oligonucleotide Proteins 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 43
- 238000009396 hybridization Methods 0.000 claims description 42
- 108020004999 messenger RNA Proteins 0.000 claims description 39
- 230000000295 complement effect Effects 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 25
- 108090000994 Catalytic RNA Proteins 0.000 claims description 24
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 102000053642 Catalytic RNA Human genes 0.000 claims description 22
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 22
- 108091092562 ribozyme Proteins 0.000 claims description 22
- 239000012636 effector Substances 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 108010057210 telomerase RNA Proteins 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 230000000692 anti-sense effect Effects 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 7
- 230000036961 partial effect Effects 0.000 claims description 7
- 239000003155 DNA primer Substances 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 230000001177 retroviral effect Effects 0.000 claims description 5
- 241000282693 Cercopithecidae Species 0.000 claims description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 3
- 239000002853 nucleic acid probe Substances 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims 1
- 229940127073 nucleoside analogue Drugs 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 98
- 239000000047 product Substances 0.000 description 62
- 108020004414 DNA Proteins 0.000 description 58
- 239000012634 fragment Substances 0.000 description 57
- 238000003556 assay Methods 0.000 description 53
- 235000001014 amino acid Nutrition 0.000 description 43
- 230000027455 binding Effects 0.000 description 31
- 108091035539 telomere Proteins 0.000 description 31
- 102000055501 telomere Human genes 0.000 description 30
- 210000003411 telomere Anatomy 0.000 description 30
- 102100031780 Endonuclease Human genes 0.000 description 25
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 24
- 101100532034 Drosophila melanogaster RTase gene Proteins 0.000 description 21
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 21
- 239000013612 plasmid Substances 0.000 description 20
- 108020004705 Codon Proteins 0.000 description 18
- 238000012300 Sequence Analysis Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 230000004927 fusion Effects 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 210000004899 c-terminal region Anatomy 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 102000006382 Ribonucleases Human genes 0.000 description 12
- 108010083644 Ribonucleases Proteins 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 108091092195 Intron Proteins 0.000 description 10
- 206010025323 Lymphomas Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000003197 catalytic effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 241000248488 Euplotes Species 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 238000012340 reverse transcriptase PCR Methods 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000001550 testis Anatomy 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 239000004677 Nylon Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 230000001293 nucleolytic effect Effects 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 241000251131 Sphyrna Species 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- -1 Cy) 5 Chemical compound 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000223892 Tetrahymena Species 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 210000003811 finger Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000248499 Euplotes aediculatus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 2
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010045292 Proto-Oncogene Proteins c-abl Proteins 0.000 description 2
- 102000005663 Proto-Oncogene Proteins c-abl Human genes 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 102000000395 SH3 domains Human genes 0.000 description 2
- 108050008861 SH3 domains Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 102000010823 Telomere-Binding Proteins Human genes 0.000 description 2
- 108010038599 Telomere-Binding Proteins Proteins 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 101150109249 lacI gene Proteins 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- 235000007708 morin Nutrition 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 238000000164 protein isolation Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 101100499417 Chlamydia pneumoniae dnaA1 gene Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical group OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101001020548 Homo sapiens LIM/homeobox protein Lhx1 Proteins 0.000 description 1
- 101000976913 Homo sapiens Lens fiber major intrinsic protein Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102100036133 LIM/homeobox protein Lhx1 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000248501 Oxytricha Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000006478 Protein Phosphatase 2 Human genes 0.000 description 1
- 108010058956 Protein Phosphatase 2 Proteins 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-LECHCGJUSA-N alpha-D-xylofuranose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-LECHCGJUSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 101150042295 arfA gene Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- MHMUIIBVMBOAON-UHFFFAOYSA-N azane;2,2,2-trichloroacetic acid Chemical compound [NH4+].[O-]C(=O)C(Cl)(Cl)Cl MHMUIIBVMBOAON-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 101150020338 dnaA gene Proteins 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 108090001052 hairpin ribozyme Proteins 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 101150087557 omcB gene Proteins 0.000 description 1
- 101150115693 ompA gene Proteins 0.000 description 1
- 101150110245 ompC gene Proteins 0.000 description 1
- 101150073640 ompF gene Proteins 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 101150040383 pel2 gene Proteins 0.000 description 1
- 101150050446 pelB gene Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 210000005238 principal cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 101150002589 recF gene Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YVSWPCCVTYEEHG-UHFFFAOYSA-N rhodamine B 5-isothiocyanate Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(N=C=S)C=C1C(O)=O YVSWPCCVTYEEHG-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220219006 rs1060501597 Human genes 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000004341 tarsal joint Anatomy 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5141097P | 1997-07-01 | 1997-07-01 | |
| US60/051,410 | 1997-07-01 | ||
| US5332997P | 1997-07-21 | 1997-07-21 | |
| US5301897P | 1997-07-21 | 1997-07-21 | |
| US60/053,329 | 1997-07-21 | ||
| US60/053,018 | 1997-07-21 | ||
| US5464297P | 1997-08-04 | 1997-08-04 | |
| US60/054,642 | 1997-08-04 | ||
| US5828797P | 1997-09-09 | 1997-09-09 | |
| US60/058,287 | 1997-09-09 | ||
| PCT/US1998/013835 WO1999001560A1 (en) | 1997-07-01 | 1998-07-01 | Vertebrate telomerase genes and proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002514928A true JP2002514928A (ja) | 2002-05-21 |
| JP2002514928A5 JP2002514928A5 (https=) | 2006-02-09 |
Family
ID=27535157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50877199A Ceased JP2002514928A (ja) | 1997-07-01 | 1998-07-01 | 脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6846662B1 (https=) |
| EP (1) | EP0917579A1 (https=) |
| JP (1) | JP2002514928A (https=) |
| KR (1) | KR100581990B1 (https=) |
| CN (1) | CN1270634A (https=) |
| AU (1) | AU748442B2 (https=) |
| CA (1) | CA2294782A1 (https=) |
| IL (1) | IL133830A0 (https=) |
| WO (1) | WO1999001560A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009502150A (ja) * | 2005-07-29 | 2009-01-29 | アンスティテュ・パストゥール | ＭＨＣクラスＩ制限ｈＴＥＲＴエピトープをコードするポリヌクレオチド、それらの類似体またはポリエピトープ |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6808880B2 (en) | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
| US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| US6777203B1 (en) | 1997-11-19 | 2004-08-17 | Geron Corporation | Telomerase promoter driving expression of therapeutic gene sequences |
| US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| EP0932686A2 (en) | 1996-10-01 | 1999-08-04 | Geron Corporation | Telomerase reverse transcriptase |
| US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
| KR100581990B1 (ko) * | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
| US7378244B2 (en) * | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
| AU1606999A (en) * | 1997-11-26 | 1999-06-15 | Albert Einstein College Of Medicine Of Yeshiva University | Mouse telomerase reverse transcriptase |
| US6608188B1 (en) | 1998-01-08 | 2003-08-19 | Chugai Seiyaku Kabushiki Kaisha | CRT-1 gene having reverse transcriptase motif |
| US6337200B1 (en) | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
| US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
| CA2347067C (en) | 1998-03-31 | 2013-09-17 | Geron Corporation | Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer |
| DE19916929A1 (de) | 1999-04-15 | 2000-10-19 | Bayer Ag | Ein automatisierbarer Schnelltest zum Nachweis von Krebserkrankungen auf der Basis von Telomerase(hTC) mRNA mit spezifischen Primern und Sonden |
| US6912492B1 (en) | 1999-05-25 | 2005-06-28 | University Of Medicine & Dentistry Of New Jersey | Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors |
| US6210950B1 (en) * | 1999-05-25 | 2001-04-03 | University Of Medicine And Dentistry Of New Jersey | Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors |
| US6664046B1 (en) * | 1999-12-16 | 2003-12-16 | Roche Molecular Systems, Inc. | Quantitation of hTERT mRNA expression |
| KR20010096991A (ko) * | 2000-04-19 | 2001-11-08 | 임정빈 | 텔로머레이즈의 프로모터에 특정하게 결합하는더블유티이1 절편, 그 유전자, 발현벡터 및 그것을 이용한세포성장 억제 방법 |
| AUPQ923400A0 (en) * | 2000-08-07 | 2000-08-31 | Children's Medical Research Institute | Assays for alternative lengthening of telomeres |
| US7078491B1 (en) | 2000-09-21 | 2006-07-18 | Amgen Inc. | Selective binding agents of telomerase |
| GB0031430D0 (en) * | 2000-12-22 | 2001-02-07 | Norsk Hydro As | Polypeptides |
| GB0112342D0 (en) * | 2001-05-21 | 2001-07-11 | Norsk Hydro As | Polypeptides |
| DK1440085T3 (da) * | 2001-10-18 | 2010-08-09 | Medicyte Gmbh | Transient immortalisering af celler af onkogene proteiner eller telomerase |
| US20060127909A1 (en) * | 2002-12-06 | 2006-06-15 | Bernd Schwenzer | Polynucleotides targeted against hter and use thereof |
| AU2007278831B2 (en) * | 2006-07-28 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| EP1994942A1 (en) * | 2007-05-25 | 2008-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions comprising telomerase, and uses thereof |
| EP2536830B1 (en) | 2010-02-16 | 2019-07-17 | Ultimovacs AS | Polypeptides |
| RU2468030C2 (ru) | 2010-04-09 | 2012-11-27 | Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова | Ингибиторы теломеразы и способ их получения |
| JP6262721B2 (ja) | 2012-05-11 | 2018-01-17 | ジェムバックス アンド カエル カンパニー，リミティド | 敗血症の予防用または治療用の組成物 |
| WO2013167298A1 (en) | 2012-05-11 | 2013-11-14 | Kael-Gemvax Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
| ES2981865T3 (es) | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo |
| US20150125438A1 (en) * | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| ES2999332T3 (en) * | 2012-09-19 | 2025-02-25 | Gemvax & Kael Co Ltd | Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate |
| CA2905961C (en) | 2013-03-15 | 2023-04-25 | Monsanto Technology Llc | Compositions and methods for the production and delivery of rna |
| WO2014171792A1 (ko) * | 2013-04-19 | 2014-10-23 | 주식회사 카엘젬백스 | 허혈성 손상 치료 및 예방용 조성물 |
| RU2677277C2 (ru) | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
| JP6495899B2 (ja) | 2013-06-21 | 2019-04-03 | ジェムバックス アンド カエル カンパニー，リミティド | ホルモン分泌調節剤、及びそれを含む組成物 |
| CN105531284B (zh) * | 2013-07-12 | 2021-03-23 | 珍白斯凯尔有限公司 | 细胞穿透肽和包含其的缀合物 |
| EP3061459B1 (en) | 2013-10-23 | 2019-12-11 | Gemvax & Kael Co., Ltd. | Composition for treating and preventing benign prostatic hyperplasia |
| KR102359396B1 (ko) | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| KR102314231B1 (ko) | 2013-12-17 | 2021-10-19 | 주식회사 젬백스앤카엘 | 전립선 암 치료용 조성물 |
| WO2015156649A1 (ko) | 2014-04-11 | 2015-10-15 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| JP6466971B2 (ja) | 2014-04-30 | 2019-02-06 | ジェムバックス アンド カエル カンパニー，リミティド | 臓器、組織又は細胞移植用組成物、キット及び移植方法 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| KR102636129B1 (ko) | 2015-02-27 | 2024-02-14 | 주식회사 젬백스앤카엘 | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 |
| KR102638286B1 (ko) | 2015-07-02 | 2024-02-20 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| CN108289909A (zh) | 2015-10-19 | 2018-07-17 | 巴尔的摩马里兰大学 | 用于产生工程改造的人原代血液树突细胞系的方法 |
| US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| CN110117644A (zh) * | 2019-04-18 | 2019-08-13 | 王金固 | 一种用于生物样本中rna的基因检测方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639613A (en) | 1992-05-13 | 1997-06-17 | Board Of Regents, University Of Texas System | Methods for cancer diagnosis and prognosis |
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5645986A (en) | 1992-05-13 | 1997-07-08 | Board Of Reagents, The University Of Texas System | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| WO1995013382A1 (en) * | 1993-11-12 | 1995-05-18 | Geron Corporation | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5972605A (en) | 1994-07-07 | 1999-10-26 | Geron Corporation | Assays for regulators of mammalian telomerase expression |
| AU696702B2 (en) * | 1994-07-07 | 1998-09-17 | Geron Corporation | Mammalian telomerase |
| EP0799315A2 (en) * | 1994-12-19 | 1997-10-08 | Cold Spring Harbor Laboratory | Telomerase protein component |
| US5770422A (en) | 1996-07-08 | 1998-06-23 | The Regents Of The University Of California | Human telomerase |
| US6261836B1 (en) * | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| EP0932686A2 (en) | 1996-10-01 | 1999-08-04 | Geron Corporation | Telomerase reverse transcriptase |
| US6093809A (en) * | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| US5919656A (en) | 1996-11-15 | 1999-07-06 | Amgen Canada Inc. | Genes encoding telomerase protein 1 |
| US7390891B1 (en) * | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
| WO1998037181A2 (en) * | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
| KR100581990B1 (ko) * | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
-
1998
- 1998-07-01 KR KR1019997012595A patent/KR100581990B1/ko not_active Expired - Fee Related
- 1998-07-01 CN CN98808383A patent/CN1270634A/zh active Pending
- 1998-07-01 EP EP98933117A patent/EP0917579A1/en not_active Withdrawn
- 1998-07-01 AU AU82854/98A patent/AU748442B2/en not_active Ceased
- 1998-07-01 WO PCT/US1998/013835 patent/WO1999001560A1/en not_active Ceased
- 1998-07-01 IL IL13383098A patent/IL133830A0/xx unknown
- 1998-07-01 CA CA002294782A patent/CA2294782A1/en not_active Abandoned
- 1998-07-01 JP JP50877199A patent/JP2002514928A/ja not_active Ceased
-
2000
- 2000-02-11 US US09/502,498 patent/US6846662B1/en not_active Expired - Fee Related
- 2000-02-11 US US09/502,424 patent/US6916642B1/en not_active Expired - Fee Related
-
2004
- 2004-07-27 US US10/900,231 patent/US20050176022A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009502150A (ja) * | 2005-07-29 | 2009-01-29 | アンスティテュ・パストゥール | ＭＨＣクラスＩ制限ｈＴＥＲＴエピトープをコードするポリヌクレオチド、それらの類似体またはポリエピトープ |
| JP2013230164A (ja) * | 2005-07-29 | 2013-11-14 | Inst Pasteur | ＭＨＣクラスＩ制限ｈＴＥＲＴエピトープをコードするポリヌクレオチド、それらの類似体またはポリエピトープ |
| JP2016104031A (ja) * | 2005-07-29 | 2016-06-09 | アンスティテュ・パストゥール | ＭＨＣクラスＩ制限ｈＴＥＲＴエピトープをコードするポリヌクレオチド、それらの類似体またはポリエピトープ |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0917579A1 (en) | 1999-05-26 |
| CN1270634A (zh) | 2000-10-18 |
| CA2294782A1 (en) | 1999-01-14 |
| US6846662B1 (en) | 2005-01-25 |
| US20050176022A1 (en) | 2005-08-11 |
| KR20010020601A (ko) | 2001-03-15 |
| IL133830A0 (en) | 2001-04-30 |
| AU8285498A (en) | 1999-01-25 |
| KR100581990B1 (ko) | 2006-05-23 |
| WO1999001560A1 (en) | 1999-01-14 |
| AU748442B2 (en) | 2002-06-06 |
| US6916642B1 (en) | 2005-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002514928A (ja) | 脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用 | |
| US6043083A (en) | Inhibitors of the JNK signal transduction pathway and methods of use | |
| JP2002525115A (ja) | 発作、高血圧、糖尿病および肥満を予報および治療する、遺伝子およびタンパク質 | |
| NZ528767A (en) | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis | |
| JP2002508662A (ja) | ヒトテロメラーゼの触媒サブユニット並びにその診断的及び治療的使用 | |
| JP2000517179A (ja) | Ｄｏｎ―１遺伝子およびポリペプチド、ならびにそれらの使用 | |
| AU770704B2 (en) | DNA polymerase lambda and uses thereof | |
| JP2001503631A (ja) | 緑内障に関連するタンパク質ならびに対応する核酸とそれらの治療および診断への利用 | |
| EP1571215A2 (en) | Vertebrate telomerase genes and proteins and uses thereof | |
| US6815532B2 (en) | ATR-2 cell cycle checkpoint | |
| US6825034B2 (en) | Human RRN3 and compositions and methods relating thereto | |
| JP2002525035A (ja) | 新規なリボゾームｓ６プロテインキナーゼの同定および機能的なキャラクタライゼーション | |
| US20030148331A1 (en) | Novel human hepatoma associated protein and the polynucleotide encoding said polypeptide | |
| JP2003503062A (ja) | タンキラーゼ２物質および方法 | |
| JP2004535781A (ja) | 新規ヒトｅｆｇファミリータンパクおよびそれをコードするポリヌクレオチド | |
| MXPA00000196A (en) | Vertebrate telomerase genes and proteins and uses thereof | |
| CA2410974A1 (en) | Polypeptides cleaving telomeric repeats | |
| JP2004537986A (ja) | 新規キナーゼおよびそれをコードするポリヌクレオチド | |
| JP2004530417A (ja) | 新規ヒトキナーゼおよびそれをコードするポリヌクレオチド | |
| JP2004524835A (ja) | 新規ヒトキナーゼおよびそれをコードするポリヌクレオチド | |
| JP5099535B2 (ja) | Ｋａｎｋ４遺伝子の癌治療及び癌検出並びに創薬への利用 | |
| WO2002064770A1 (fr) | Nouvelle proteine de classe a du type recepteur eboueur | |
| US20040005658A1 (en) | Novel polypeptide-human an1-like protein 16 and the polynucleotide encoding the same | |
| HK1032074A (en) | Vertebrate telomerase genes and proteins and uses thereof | |
| WO2001079467A2 (en) | Identification of a renal nadph oxidase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050630 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050816 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070612 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070911 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071022 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080123 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080304 |